Nuvation Bio (NUVB) stock is in focus after the U.S. FDA granted Fast Track Designation to safusidenib for IDH1-mutant glioma, following clinical data showing durable responses and a favorable risk-benefit profile.

At a latest share price of US$6.93, Nuvation Bio has seen a 46.82% 90 day share price return and a very large 3 year total shareholder return, although the year to date share price return is down 19.23%, which suggests momentum has picked up more recently alongside clinical progress.

If this kind of move in Nuvation Bio has your attention, it can be useful to see what else is setting up in the sector, starting with 40 healthcare AI stocks.

Bulls view Nuvation Bio as a high potential oncology platform now trading on fresh Fast Track momentum. Bears point to ongoing losses and execution risk. Which story do the current valuation signals lean toward next?

Most Popular Narrative: 47.1% Undervalued

At a last close of $6.93, the most followed narrative for Nuvation Bio points to a fair value of about $13.11, anchored on a detailed long term glioma and IBTROZI thesis built using a 7.24% discount rate.

Advancement of safusidenib into a pivotal Phase III high grade IDH1 mutant glioma maintenance study, targeting a population underserved by existing therapies, could position the company to tap into a durable brain tumor market and add a second meaningful revenue pillar that has the potential to scale earnings beyond IBTROZI.

Want to see what kind of revenue ramp and margin shift that second pillar assumes? The narrative leans on aggressive growth, rising profitability and a very demanding future earnings multiple. The model connects those pieces into a single fair value number.

Result: Fair Value of $13.11 (UNDERVALUED)

However, the Nuvation Bio narrative still depends on long duration safusidenib trials and assumptions about IBTROZI competition that could shift and challenge today’s valuation case.

Another View on Nuvation Bio’s Valuation

The SWS fair ratio points in a different direction. Nuvation Bio trades on a P/S of 14.3x, compared with a US Pharmaceuticals average of 5.4x, a peer average of 14.1x and a fair ratio of 13.4x that the market could move toward. That leans toward richer pricing. How comfortable are you with paying up for this growth story?

Next Steps

With sentiment clearly split on Nuvation Bio, this is a moment to move quickly and check the underlying data for yourself before views harden. Start by weighing the 2 key rewards.

Looking for more investment ideas beyond Nuvation Bio?

If Nuvation Bio has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to line up your next set of potential opportunities.

• Target resilient compounders that prioritize stability and downside protection through the 75 resilient stocks with low risk scores.
• Hunt for quality at a potential discount by scanning the 48 high quality undervalued stocks.
• Spot companies with stronger cash buffers and cleaner finances through the solid balance sheet and fundamentals stocks screener (50 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.